scholarly journals Intramedullary thoracic spinal metastasis from small-cell lung cancer

2013 ◽  
Vol 79 (3-4) ◽  
Author(s):  
S. Katsenos ◽  
M. Nikolopoulou
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Spinal Metastasis ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Thoracic Spinal

Intramedullary thoracic spinal metastasis from small-cell lung cancer. S. Katsenos, M. Nikolopoulou. Lung cancer with intramedullary spinal cord metastasis (ISCM) is a rare event exhibiting dismal prognosis. In the present paper, we describe a 74-year-old male who developed bilateral leg weakness with associated backache and non-productive cough. Chest imaging evaluation demonstrated pronounced bilateral mediastinal lymphadenopathy and a nodular opacity in the right lower lobe. The patient was diagnosed with small cell lung cancer through bronchoscopic procedures. Magnetic resonance imaging of the spinal cord with contrast-enhancement revealed an intramedullary lesion consistent with metastasis at the T5-T6 level. Despite chemotherapy and thoracic spine radiotherapy, he eventually succumbed to the disease 3 months after diagnosis. A brief overview of the current literature is also provided laying emphasis on the therapeutic strategies of this unusual extrathoracic metastatic disease.

Intramedullary Spinal Cord Metastasis (ISCM) Arising from Small Cell Lung Cancer (SCLC)

2010 ◽  
Vol 45 (1) ◽  
pp. 78
Author(s):  
Sang-Bum Kim ◽  
Byung-Hak Oh ◽  
Seong-Kwon Cho ◽  
Cheol-Mog Hwang ◽  
Youn-Moo Heo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Spinal Cord Metastasis ◽  
Intramedullary Spinal Cord Metastasis

Intramedullary Spinal Cord Metastases Due to Non–small-cell Lung Cancer

2008 ◽  
Vol 18 (1) ◽  
pp. 54-56
Author(s):  
Meftun Unsal ◽  
Cengiz Cokluk ◽  
Hande Turker
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord

scholarly journals Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long-term Survivor with Metastatic Non–Small-Cell Lung Cancer

2014 ◽  
Vol 9 (8) ◽  
pp. e60-e61
Author(s):  
Kristin N. Arreola ◽  
James Ying ◽  
Randall Hughes ◽  
David E. Gerber ◽  
D.W. Nathan Kim
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Term Survivor

scholarly journals A case of small cell lung cancer with intramedullary spinal cord metastasis

2005 ◽  
Vol 42 (5) ◽  
pp. 567-570 ◽  
Author(s):  
Aki Kato ◽  
Hitoshi Katayama ◽  
Hironobu Hamada ◽  
Tomoaki Nagao ◽  
Toru Kadowaki ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Spinal Cord Metastasis ◽  
Intramedullary Spinal Cord Metastasis

scholarly journals A Case of Intramedullary Spinal Cord Metastasis From Non-small Cell Lung Cancer

2002 ◽  
Vol 52 (6) ◽  
pp. 627
Author(s):  
Sang Woo Park ◽  
Hyung Soo Wi ◽  
Hoon Soo Kim ◽  
Jae Hwa Cho ◽  
Hong Lyeol Lee ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord ◽  
Spinal Cord Metastasis ◽  
Intramedullary Spinal Cord Metastasis

Intramedullary spinal cord metastases in a patient with small-cell lung cancer

2006 ◽  
Vol 17 (5) ◽  
pp. 372-374 ◽  
Author(s):  
Georgios Koutsis ◽  
Konstantinos Spengos ◽  
Constantin Potagas ◽  
Antonios Dimitrakopoulos ◽  
Konstantinos Sfagos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord

Intramedullary Spinal Cord Metastases from Atypical Small Cell Lung Cancer: A Case Report and Literature Review

2006 ◽  
Vol 24 (1) ◽  
pp. 46-49 ◽  
Author(s):  
Maria Nikolaou ◽  
Maria Koumpou ◽  
Nicolaos Mylonakis ◽  
Athanasios Karabelis ◽  
Dimitris Pectasides ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Case Report ◽  
Literature Review ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord

scholarly journals Intramedullary Spinal Cord Metastases from Small Cell Lung Cancer: Report of One Case and Review of the Literature

2021 ◽  
Author(s):  
Huanbing Lu ◽  
Jinfeng Liu ◽  
Chenglong Sun ◽  
Zhanggu Wang
Keyword(s):  
Lung Cancer ◽  
Spinal Cord ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Intramedullary Spinal Cord

Abstract Purpose Spinal cord intramedullary metastasis (ISCM) is a rare malignant tumor of the nervous system. Small cell lung cancer (SCLC) accounts for about 15% of lung cancer, and the incidence of brain metastasis is high, but intramedullary spinal cord metastasis is rare. In recent years, the first-line treatment of patients with ISCM from SCLC has been controversial. For these patients with ISCM, the options are usually depending on the progression of the disease.However,the outcom of treatments are not satisfacted.Thus,We try to indentify the use of immunotherapy in ISCM from SCLC. Methods In our review, we focused on clinical trials of immunotherapy, especially in relation to ISCM in SCLC. Results A patient was diagnosed as ISCM from SCLC. Radiotherapy for ISCM was started on January 11, 2021 Apatinib was taken orally after radiotherapy. The overall survival was almost 8 months, and there was only 1 month after ISCM was diagnosed. Conclusion Finding practical treatment options for SCLC is an important goal. Previous trials have shown that immunotherapy with checkpoint inhibitors may be an effective approach for long-term disease control and a new breakthrough in the treatment of ISCM form SCLC.

Small-Cell Lung Cancer Comorbid with Pulmonary Mycobacterium avium Infection: A Case Report

Chemotherapy ◽  
2018 ◽  
Vol 63 (5) ◽  
pp. 257-261
Author(s):  
Masahiro Yamasaki ◽  
Kunihiko Funaishi ◽  
Naomi Saito ◽  
Ken-ichi Sakamoto ◽  
Sayaka Ishiyama ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mycobacterium Avium ◽  
Cell Lung Cancer ◽  
Left Lung ◽  
Small Cell ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Before And After ◽  
Avium Infection

Background: Small-cell lung cancer (SCLC) rarely coexists with pulmonary Mycobacterium avium intracellular complex (MAC) infection. The key drug for SCLC treatment is etoposide, which is metabolized by cytochrome P-450 (CYP) 3A4. Meanwhile, the key drugs for pulmonary MAC infection are clarithromycin (CAM) and rifampicin (RFP), and their metabolism influences CYP3A4. Therefore, treatment of concurrent SCLC and pulmonary MAC infection is difficult, and to the best of our knowledge, no report of treatments for concurrent SCLC and pulmonary MAC infection has been published. Patient Concerns and Diagnoses: A 65-year-old man presented to our hospital with abnormal findings of chest computed tomography: (1) a hilar region nodule in the left lung and mediastinal lymphadenopathy and (2) a thick-walled cavity lesion in the right upper lobe of the lung. After further examinations, the former lesions were diagnosed as SCLC, cT4N3M0, stage IIIC and the latter as pulmonary MAC infection, fibrocavitary disease. Interventions and Outcomes: Concurrent treatment was conducted with discontinuation of CAM and RFP before and after etoposide administration. Specifically, intravenous cisplatin and etoposide were administered on day 1 and days 1–3, respectively, and CAM, RFP, and ethambutol (EB) were administered orally on days 6–22 every 4 weeks. Concurrent radiotherapy was added to the drug administration on days 1–27 of the first cycle. The chemotherapy was continued for 4 cycles, followed by continuation of CAM and RFP administration. EB was discontinued because of optic nerve disorder. The treatments were conducted completely and safely, and both of the SCLC lesions and the MAC lesion were improved. Conclusions: Treatments for concurrent SCLC and pulmonary MAC infection may be successfully conducted with discontinuation of CAM and RFP before and after etoposide administration.

Sign in / Sign up

Export Citation Format

Share Document